Over 40 years of experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, micro-cap companies, and the development and licensing of emerging technologies. Capital raises in excess of $200 million. Expertise in public corporate governance, board of director duties and responsibilities, and financial expertise required for audit committee membership. Since April of 2018 Mr. Berman has been the Chief Executive Officer and a member of the Board of Directors of enVVeno Medical Corporation, during which time he has successfully transitioned the company from being a small private company focused on cardiac care, to a publicly traded entity focused on the treatment of venous disease. Prior to enVVeno Medical, he served as the President, Chief Executive Officer, and a member of the Board of Directors of ITUS Corporation (now called Anixa Biosciences), which he transitioned from being a developer of thin-film display technologies into a Nasdaq listed cancer therapeutics company. Mr. Berman was also the Chief Operating Officer and General Counsel of Acacia Research Corporation, the preeminent, publicly traded company for licensing and enforcing patented technologies, which grew to a market cap exceeding $2 billion. Mr. Berman started his career as an attorney at the law firm of Blank Rome. He holds a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and a J.D. from the Northwestern University School of Law, where he has been an adjunct faculty member.Specialties: CEO Responsibilities, Startups, Technology Development and Licensing, Turnarounds, Healthcare, Public Company Governance, Capital Raises, Micro-cap, Med-Tech, Board of Directors, Financial Expertise for Audit Committees